Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. (SCLC)
A Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Chiauranib for the Treatment of Advanced Solid Tumors and Relapsed/Refractory SCLC
Sponsor: Chipscreen Biosciences, Ltd.
A PHASE1/PHASE2 clinical study on Advanced Solid Malignant Tumor and Small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by Chipscreen Biosciences, Ltd. and has accumulated 13 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2023 — Apr 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 8 earlier versions
-
Apr 2023 — Aug 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2022 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE1_PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chipscreen Biosciences, Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .